HAVAS B V by HAVAS B V Stock (OTC: HVBVF)

Latest news for HAVAS B V by HAVAS B V (OTC:HVBVF) Stock

HAVAS B V by HAVAS B V

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">expect in the report.&nbsp;</a>
What To Watch: Investors will be looking for updates on Moderna&#8217;s portfolio of mRNA-based vaccines and treatments across infectious diseases, immuno-oncology and rare diseases. COVID-19 vaccine demand and sales will be on watch.&nbsp;
Bird flu continues to spread through wild birds, poultry farms and cattle herds and updates on Moderna's development of an avian flu vaccine candidate should be watched closely.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a>
Outspoken vaccine skeptic Robert F. Kennedy was sworn in as the<a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health"> new secretary</a> of Health and Human Services on Thursday and may enact policy changes that could affect regulations and Moderna's business. Executives may offer some commentary in the company's earnings call scheduled for 8 a.m. ET on Friday.&nbsp;&nbsp;
What Else: Goldman Sachs analyst Salveen Richter <a href="https://www.benzinga.com/25/01/43314068/moderna-stock-is-sliding-wednesday-heres-why">recently downgraded </a>Moderna from Buy to Neutral and lowered the price target from $99 to $51, citing lower conviction following a second product revenue guidance adjustment from the company.
According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect Moderna to report quarterly losses of $2.68 per share and revenue of $942.84 million. The company has beat consensus estimates on the top and bottom lines for the last four consecutive quarters.&nbsp;
MRNA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Moderna shares ended Thursday's session up 4.54% at $31.92.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a></li>
</ul>
Image: Shutterstock

Earnings

News

Health Care

Previews

Politics

Movers

General

MRNA

Moderna Q4 Earnings Preview: COVID-19 Vaccine Sales, Bird Flu Vaccine Candidates On Watch

Canaccord Genuity analyst Joseph Vafi maintains Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) with a Buy and maintains $13 price target.

Price Target

Analyst Ratings

RPAY

Canaccord Genuity Maintains Buy on Repay Holdings, Maintains $13 Price Target

Canaccord Genuity analyst Joseph Vafi maintains Pagaya Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) with a Buy and maintains $25 price target.

Canaccord Genuity Maintains Buy on Pagaya Techs, Maintains $25 Price Target

Tigress Financial analyst Ivan Feinseth maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Strong Buy and raises the price target from $550 to $685.

Tigress Financial Maintains Strong Buy on Mastercard, Raises Price Target to $685

Seaport Global analyst Mark Weintraub upgrades Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) from Neutral to Buy and announces $250 price target.

Upgrades

Seaport Global Upgrades Packaging Corp of America to Buy, Announces $250 Price Target

Citigroup analyst Joanne Wuensch maintains GE HealthCare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) with a Buy and raises the price target from $103 to $110.

GEHC

Citigroup Maintains Buy on GE HealthCare Techs, Raises Price Target to $110

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Buy and raises the price target from $22 to $30.

INMB

Maxim Group Maintains Buy on INmune Bio, Raises Price Target to $30

Maxim Group analyst Anthony Vendetti maintains Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) with a Buy and raises the price target from $50 to $75.

NUTX

Maxim Group Maintains Buy on Nutex Health, Raises Price Target to $75

Lake Street analyst Ben Klieve maintains Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) with a Buy and raises the price target from $60 to $68.

CHEF

Lake Street Maintains Buy on Chefs' Warehouse, Raises Price Target to $68

Nukkleus has also submitted a Form S-1 registration statement registering for resale the shares of common stock issued or issuable in connection with its recent &nbsp;$10 million private placement which further reinforced its financial foundation for the Star 26 acquisition and future expansion.

NUKK

Nukkleus Formally Submits Preliminary Proxy To SEC With Respect To Proposed Acquisition Of Star 26 Capital

Lake Street initiates coverage on TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) with a Buy rating and announces Price Target of $10.

Initiation

TLSI

Lake Street Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $10

It is payable on March 26, 2025 to stockholders of record as of the close of business on March 14, 2025.

Dividends

Meta Platforms Boosts Quarterly Cash Dividend By 5% From $0.50 To $0.525 Per Share

Loop Capital analyst Garik Shmois maintains Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Buy and lowers the price target from $680 to $645.

Loop Capital Maintains Buy on Martin Marietta Materials, Lowers Price Target to $645

Loop Capital analyst Alan Gould maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and raises the price target from $180 to $210.

RDDT

Loop Capital Maintains Buy on Reddit, Raises Price Target to $210

Jefferies analyst Randal Konik maintains SharkNinja (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) with a Buy and raises the price target from $150 to $175.

Jefferies Maintains Buy on SharkNinja, Raises Price Target to $175

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $28 to $17.

STAA

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $17

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Buy and lowers the price target from $20 to $18.

Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $18

This dividend is payable on March 5, 2025 to shareholders of record on February 24, 2025. This dividend rate equates to an annualized dividend of $1.87 per share.

CHCT

Community Healthcare Trust Boosts Quarterly Dividend From $0.4650 To $0.4675 Per Share

Offerings

Gen Digital Prices $950M Of Its 6.25% Senior Notes Due 2033, Which Were Offered In Private Offering

The sanction hearing for the Royal Court of Jersey (the "Court") to hear Arcadium Lithium's application to sanction the scheme of arrangement under Part 18A of the Companies (Jersey) Law 1991 has been set on March 5, 2025 at 5:00 a.m. EST (9:00 p.m. AEDT), with closing of the Transaction expected to occur shortly thereafter on March 6, 2025.
 &nbsp;

Comments

HAVAS B V by HAVAS B V

News

Latest news for HAVAS B V by HAVAS B V (OTC:HVBVF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga